A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease

Phase 2TerminatedNCT02245412

Alexion Pharmaceuticals, Inc.25 enrolled

Overview

The objectives of this trial were to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of intravenous (IV) ALXN1007 in participants with acute graft-versus-host disease (GVHD) of the lower gastrointestinal (GI) tract.

This was a Phase 2A open-label, non-randomized study to evaluate the safety, tolerability, PK/PD, and efficacy of ALXN1007 (a C5a inhibitor) in up to 36 participants with newly diagnosed acute GVHD of the lower GI tract. All participants meeting the inclusion and exclusion criteria for the study were to receive ALXN1007 over an 8 week treatment period. Participants in Cohort 1, the first dosing cohort, were to receive 10 milligrams/kilogram (mg/kg) ALXN1007 administered IV once weekly for 8 weeks. Participants in Cohort 2 were to receive 20 mg/kg ALXN1007 IV once weekly for 8 weeks. Participants in Cohort 3 were to receive 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. All doses of ALXN1007 were to be administered as a continuous IV infusion.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Graft-Versus-Host Disease GIGVHD

Interventions

ALXN1007 10 mg/kg once weeklyBIOLOGICAL

ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

ALXN1007 20 mg/kg once weeklyBIOLOGICAL

ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

ALXN1007 20 mg/kg twice weeklyBIOLOGICAL

ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants must be males or females age 18 years or older. * Participants with Stage 1 to 4 (per the Modified Keystone Grading Schema) acute GVHD of the lower GI tract, without signs of chronic GVHD, at the time of diagnosis, which developed in the first 180 days following allogeneic hematopoietic cell transplantation (HCT) using bone marrow, peripheral blood, or cord blood; or after preplanned donor lymphocyte infusion. * Participants are willing to undergo or must have had an endoscopy of the upper and/or lower GI tract and biopsy to confirm GI GVHD. * Participants must be receiving systemic corticosteroids. * Participants with an absolute neutrophil count (ANC) \>500/microliter (μL) at Screening. * Participants and spouse/partner who are of childbearing potential must be using high effective contraception consisting of 2 forms of birth control (at least 1 of which much be barrier method) starting at Screening and continuing through the entire study (for at least 3 months after the last dose of ALXN1007 if study treatment is stopped early or participant withdraws consent). * Male participants must not donate sperm during the Screening and Treatment periods, and for at least 3 months after the last dose of ALXN1007. * Stage of acute GVHD of the lower GI tract will be determined using the Modified Keystone Grading Schema. Exclusion Criteria: * Participants with a body weight \> 140 kg (for Cohorts dosing 20 mg/kg of ALXN1007 and higher only). * Participants with signs and symptoms of chronic GVHD. * Participants with an active uncontrolled infection. * Participants who test positive for Clostridium difficile (C. difficile) at Screening. * Participants with relapsed/persistent malignancy requiring rapid immune suppression withdrawal. * Participants who received an unplanned (not part of the original transplant therapy plan) donor lymphocyte infusion. * Participants who received previous systemic treatment for acute GVHD, except for a maximum of 3 days (72 hours) of 2 mg/kg corticosteroid therapy. * Participants with unresolved veno-occlusive disease of the liver. * Participants with creatinine clearance \<40 milliliters (mL)/minute at Screening, as calculated by the Cockcroft-Gault formula. * Participants known to be infected with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. * Participants known to have an uncontrolled thyroid disorder. * Participants who are pregnant, breast feeding, or sexually active and unwilling to use effective birth control for the duration of the study. * Participants who participated in any other investigational drug trial or had exposure to any other investigational agent, device, or procedure \<4 weeks prior to Screening and throughout the entire trial, with the exception of investigational drugs administered prophylactically for cytomegalovirus (CMV) post allogeneic HCT.

Locations (12)

City of Hope

Duarte, California, United States

Emory University Hospital

Atlanta, Georgia, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Outcomes

Primary Outcomes

Overall Acute Graft-Versus-Host Disease (GVHD) Response Rate At Day 28

The number of participants with overall acute GVHD response was determined at Day 28. Acute Overall GVHD is defined as improvement from diagnosis in any organ by at least 1 stage, without progression in any other organ, and with no additional therapy being administered. Acute GVHD staging included skin, liver, and GI assessments, which were to be performed using the Modified Keystone Grading Schema. Deaths were considered nonresponders; otherwise last postbaseline values were carried forward for imputation of missing responses. Modified Keystone Grading Schema: Skin - Stages 0 = No Rash, 1 = Rash \<25% body surface area (BSA), 2 = 25% to 50% BSA, 3 = \>50% BSA, 4 = bullae, desquamation; Lower GI Tract (stool volume over 24 hours) - Stages 0 = \<500 mL, 1 = 500 to 1000 mL, 2 = 1001 to 1500 mL, 3 = \>1500 mL, 4 = severe abdominal pain +/- ileus, frank blood, or melena; Liver (bilirubin levels) - Stages 0 = ≤2 mg/dL, 1 = 2.1 to 3 mg/dL, 2 = 3.1 to 6 mg/dL, 3 = 6.1 to 15 mg/dL, 4 = \>15 mg/dL.

Time frame: Day 28

Secondary Outcomes

Pharmacokinetics (PK): Time To Maximum Observed Concentration In Plasma (Tmax) Of IV ALXN1007

The Tmax of ALXN1007 was measured on Treatment Days 1, 28, and 49, from blood samples collected at time points relative to the dosing of ALXN1007. PK assessments were to have been measured from Baseline, Treatment Days 7, 14, 21, 28, 35, 42, 49, 56, and Follow-up Days 86, 180, and Early Termination (ET). Due to the early termination of the study and the clinical development of the ALXN1007 program, a number of PK analyses were not completed. PK data for the 20 mg/kg ALXN1007 once weekly dosing group and the 20 mg/kg ALXN1007 twice weekly dosing group are not available.

Time frame: Predose up to 72 hours postdose

PK: Maximum Observed Concentration In Plasma (Cmax) Of IV ALXN1007

The Cmax of ALXN1007 was measured on Treatment Days 1, 28, and 49, from blood samples collected at time points relative to the dosing of ALXN1007. PK assessments were to have been measured from Baseline, Treatment Days 7, 14, 21, 28, 35, 42, 49, 56, and Follow-up Days 86, 180, and Early Termination (ET). Due to the early termination of the study and the clinical development of the ALXN1007 program, a number of PK analyses were not completed. PK data for the 20 mg/kg ALXN1007 once weekly dosing group and the 20 mg/kg ALXN1007 twice weekly dosing group are not available.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.